Asarina Pharma: Redeye reports positively on new directed share issue
October 25, 2019: Redeye: “We see Asarina Pharma as one of the truly undiscovered biotech cases on the Scandinavian stock markets. We argue that the prospects for showing good results in its PMDD Phase IIb Study are good, which is not at all reflected in the stock price at present.”
Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects
Stockholm, June 12 2019: A new paper in the Journal of Neuroendocrinology shows how Asarina Pharma’s compound Sepranolone reduced tics in an animal model of Tourette syndrome as effectively as current first-line treatment Haldol—without inducing any motor side effects.
Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11
Stockholm, June 11, 2019: Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO’s new International Classification of Diseases, ICD-11. “This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication” says CEO…
PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day
(Stockholm May 23, 2019) Valuable knowledge about PMS & PMDD will be shared at the University of Gothenburg on May 28 at a public evening of talks, lectures and Q&A. Prof Torbjörn Bäckström, PMDD research pioneer and Asarina Pharma CSO, will speak about the science and treatment of PMDD.